Skip NavigationSkip to Content

The adaptor protein TRAF3 is an immune checkpoint that inhibits myeloid-derived suppressor cell expansion

  1. Author:
    Zhu, Sining
    Lalani, Almin I
    Jin, Juan
    Sant'Angelo, Derek
    Covey, Lori R
    Liu, Kebin
    Young,Howard
    Ostrand-Rosenberg, Suzanne
    Xie, Ping
  2. Author Address

    Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, United States., Graduate Program in Cellular and Molecular Pharmacology, Rutgers University, Piscataway, NJ, United States., Department of Pharmacology, Anhui Medical University, Hefei, Anhui, China., Child Health Institute of New Jersey, Rutgers University, New Brunswick, NJ, United States., Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, United States., Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States., Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA, United States., Laboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, United States., Department of Biological Sciences, The University of Maryland, Baltimore County, Baltimore, MD, United States.,
    1. Year: 2023
    2. Epub Date: 2023 05 03
  1. Journal: Frontiers in Immunology
    1. 14
    2. Pages: 1167924
  2. Type of Article: Article
  3. Article Number: 1167924
  1. Abstract:

    Myeloid-derived suppressor cells (MDSCs) are aberrantly expanded in cancer patients and under other pathological conditions. These cells orchestrate the immunosuppressive and inflammatory network to facilitate cancer metastasis and mediate patient resistance to therapies, and thus are recognized as a prime therapeutic target of human cancers. Here we report the identification of the adaptor protein TRAF3 as a novel immune checkpoint that critically restrains MDSC expansion. We found that myeloid cell-specific Traf3-deficient (M-Traf3-/-) mice exhibited MDSC hyperexpansion during chronic inflammation. Interestingly, MDSC hyperexpansion in M-Traf3-/- mice led to accelerated growth and metastasis of transplanted tumors associated with an altered phenotype of T cells and NK cells. Using mixed bone marrow chimeras, we demonstrated that TRAF3 inhibited MDSC expansion via both cell-intrinsic and cell-extrinsic mechanisms. Furthermore, we elucidated a GM-CSF-STAT3-TRAF3-PTP1B signaling axis in MDSCs and a novel TLR4-TRAF3-CCL22-CCR4-G-CSF axis acting in inflammatory macrophages and monocytes that coordinately control MDSC expansion during chronic inflammation. Taken together, our findings provide novel insights into the complex regulatory mechanisms of MDSC expansion and open up unique perspectives for the design of new therapeutic strategies that aim to target MDSCs in cancer patients. Copyright © 2023 Zhu, Lalani, Jin, Sant’Angelo, Covey, Liu, Young, Ostrand-Rosenberg and Xie.

    See More

External Sources

  1. DOI: 10.3389/fimmu.2023.1167924
  2. PMID: 37207205
  3. PMCID: PMC10189059

Library Notes

  1. Fiscal Year: FY2022-2023
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel